Carefully designed pulmonary fibrosis models.

Understanding the pathology behind pulmonary fibrosis demands an in-depth analysis of several complex dysregulated pathways that include multiple types of cells, namely macrophages, fibroblasts and epithelial cells. Till today, there still aren’t any drugs that specifically target idiopathic pulmonary fibrosis.

Developing effective therapeutic drugs for pulmonary fibrosis depends on the availability of accurate and reliable animal models that can replicate the pathological manifestations of the disease, animal models that are available at PharmaLegacy. Reach out to our experts for more information, and let’s move your pipelines forward.

Contact Us
Pulmonary Fibrosis


Case Study: Bleomycin-induced Pulmonary Fibrosis in C57BL/6 Mice

Animal: C57BL/6 Mice, Male, 22-25.

Material: Bleomycin

Methods:  Bleomycin solution is given to mice via intratracheal instillation.


Endpoint: Body Weight and Survival Rate

Endpoint: Histological Evaluation

Endpoint: Masson Trichrome Staining ( x 20)

· Intratracheal administration of bleomycin induced pulmonary fibrosis on the basis of histological examination displaying fibrotic thickening and epithelial hyperplasia.

· Hydroxyproline in lungs with pulmonary fibrosis was increased significantly which is consistent with fibrotic characterization.

Where pharmacology meets excellence:

  • Operations and IT structured for maximum protection of clients’ data and IP
  • Capacity to run 200+ concurrent animal studies
  • 380,000 square feet of facility space
  • FDA Part 11 compliant

If uncompromised commitment is what you are looking for in a CRO, you’ve come to the right place. Get in touch with our experts at PharmaLegacy now.

Contact Us

We’re ready when you are.

Tell us your pharmacology challenges.